Source: International Congress 2017 – IPF: from the bench to the bedside
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Ikeda (Sapporo, Japan). Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone. 3808

Member's Comments

No comment yet.

Related content which might interest you: Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009 Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Source: Eur Respir J 2016; 48: 843-851 Year: 2016 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Enhanced effects of pirfenidone on the early phase of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis Source: Eur Respir J 2002; 19: 439-446 Year: 2002 Prognostic role of CCL18 serum concentrations in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020 Recombinant thrombomodulin improves survival in acute exacerbation of idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Vulnerability of fatal infection under steroid treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2002; 20: Suppl. 38, 354s Year: 2002 Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018